Skip to main content
. 2019 Jun 20;6(4):774–783. doi: 10.1002/ehf2.12454

Figure 3.

Figure 3

Percentage of patients at each dosing level among all patients (left of paired bar graphs) and eligible patients (right of paired bar graphs). ACE‐I/ARB, angiotensin‐converting enzyme inhibitors or angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.